



Invesco Small Cap Growth Portfolio

Quarterly Performance Commentary

CUSIPS: A:76222X828 C:76222X810 I:76222X778

Investment objective

The portfolio seeks long-term growth of capital.

Portfolio management

Juan R. Hartsfield, Clay Manley

Management is that of the underlying fund.

Portfolio information

Total net assets \$13,121,838

Total number of holdings 119

Holdings shown are that of the underlying fund.

Top equity holdings

Top equity holdings	% of total net assets
Q2 Holdings	1.71
Chemed	1.50
TransDigm	1.48
CoreSite Realty	1.40
Martin Marietta Materials	1.40
Bio-Techne	1.35
Realpage	1.32
Silicon Laboratories	1.27
Repligen	1.27
Aspen Technology	1.22

Holdings are that of the underlying fund, subject to change and are not buy/sell recommendations.

Top contributors

Top contributors	% of total net assets
1. Martin Marietta Materials	1.40
2. TransDigm	1.48
3. Chemed	1.50
4. Natera	1.05
5. Nevro	0.65

Data shown is that of the underlying fund.

Top detractors

Top detractors	% of total net assets
1. Sarepta Therapeutics	0.63
2. ICU Medical	0.08
3. GW Pharmaceuticals	0.67
4. Amicus Therapeutics	0.59
5. Agios Pharmaceuticals	0.55

Data shown is that of the underlying fund.

Portfolio commentary provided is based on the underlying fund.

Market overview

- Key issues that concerned investors in the second quarter carried over into the third quarter.
- US-China trade conflict worried investors and stifled business investment even as the Federal Reserve cut interest rates by 0.25% in July and September.
- The US Treasury yield curve inverted several times, raising fears of a US recession. However, the Fed's accommodative tone provided some support for risk assets.
- Despite increased volatility, US equity markets delivered generally positive results.

Performance highlights

- The portfolio's Class A units at net asset value (NAV) declined for the quarter and underperformed the Russell 2000 Growth Index. (Please see the investment results table on page 2 for fund and index performance.)
- The health care and industrials sectors were the leading detractors from relative return due to stock selection. Health care has come under pressure from a heavily politicized environment ahead of the 2020 presidential election.
- Stock selection and an underweight in consumer staples was another notable detractor.
- Key contributors to relative return included stock selection in the information technology, communication services and consumer discretionary sectors.

Contributors to performance

- **Martin Marietta Materials** supplies aggregates and building materials and has benefited from strong pent-up demand after several years of bad weather caused project delays. **Martin Marietta** also declared a special dividend.
- **TransDigm** is a global producer, designer and supplier of engineered aerospace components, systems and sub-systems. The company has delivered strong organic growth and good cost synergies from its Esterline Technologies (not a fund holding) acquisition.
- **Chemed** operates in two business areas - home hospice care and Roto-Rooter plumbing. The company benefited from the finalization of favorable hospice reimbursement changes by the Centers for Medicare & Medicaid Services, which is perceived to be a potentially meaningful tailwind to the company's 2020 earnings. The company has shown consistent execution while delivering attractive growth and profit margins in both business segments.

Detractors from performance

- **Sarepta Therapeutics** is a medical research and drug development company. The stock suffered along with underperformance of the broader biotechnology group as bipartisan support for legislative action on drug pricing gained momentum. **Sarepta Therapeutics** also faced broader management credibility concerns.
- **ICU Medical** develops medical devices. During the quarter, management unexpectedly lowered earnings guidance for its IV Solutions business due to profit margin pressures from increased competition. The company has decided to exit this business segment to focus on areas that offer long-term contracts.
- **GW Pharmaceuticals**, a UK-based biopharmaceutical company known for its cannabinoid multiple sclerosis treatment, came under pressure amid underperformance of the broader biotech group. There are also concerns about a waning of high pent-up demand for the first FDA-approved CBD product, which led to a strong launch of EPIDIOLEX, its CBD seizure treatment.

Positioning and outlook

- All positioning changes are based on bottom-up stock selection.
- Our long-term investment horizon results in relatively low portfolio turnover, while disciplined portfolio construction acts as a risk control and ensures alignment with small-cap market sector exposure with modest over- and underweights.
- Recent central bank actions have supported continued growth by keeping the cost of debt low. The labor market remains healthy with job and wage gains; thus, consumers appear to be fine. However, these are clearly the late innings of the economic cycle and we, therefore, expect only modest growth from here, as well as continued volatility spurred by trade and election headlines.
- True growth is likely to be scarce and we believe the market will favor companies that can produce growth and compound earnings despite the economic cycle.

Investment results


Average annual total returns (%) as of Sept. 30, 2019

Period	Class A units		Class C units		Class I units	Style-Specific Index
	Inception: 07/08/16 Max Load 4.00%	NAV	Inception: 07/08/16 Max CDSC 1.00%	NAV	Inception: 07/08/16 NAV	Russell 2000 Growth Index
Inception	9.50	10.90	10.14	10.14	11.17	-
3 Years	8.66	10.16	9.37	9.37	10.41	9.79
1 Year	-13.61	-9.99	-11.55	-10.66	-9.80	-9.63
Quarter	-8.75	-4.97	-6.02	-5.07	-4.93	-4.17

The performance quoted is past performance and is not a guarantee of future results. Investment returns and principal value of an investment will fluctuate so that an account owner's units, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance data shown. For up-to-date month-end performance information please call 877 615 4116, or visit collegebound529.com. Performance figures reflect reinvested distributions of the underlying security and changes in net asset value (NAV). No contingent deferred sales charge (CDSC) will be imposed on redemptions of Class C units following one year from the date units were purchased. Performance shown at NAV does not include applicable CDSC or front-end sales charges, which would have reduced the performance. Class I units have no sales charge; therefore, performance is at NAV. Returns less than one year are cumulative; all others are annualized. Index returns do not reflect any fees, expenses, or sales charges.

Index source: Invesco

The portfolio's positioning versus the Russell 2000 Growth Index (% underweight/overweight)



Data shown is that of the underlying fund.

Asset mix (%)

Dom Common Stock	97.11
Intl Common Stock	1.35
Cash	1.10
Other	0.44

Data shown is that of the underlying fund.

Expense ratios (%)

Class A units	1.16
Class C units	1.91
Class I units	0.91

Total annual asset-based fee per the current Program Description.

For more information you can visit us at collegebound529.com

Class I units are available only to certain investors. See the Program Description for more information.

The underlying fund holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and service mark of MSCI Inc. and Standard & Poor's.

The Russell 2000® Growth Index is an unmanaged index considered representative of small-cap growth stocks. The Russell 2000 Index is a trademark/service mark of the Frank Russell Co. Russell® is a Trademark of the Frank Russell Co. An investment cannot be made directly in an index.

The S&P 500® Index is an unmanaged index considered representative of the US stock market. An investment cannot be made directly in an index.

About risk

Risks of the Underlying Holding

The risks of investing in securities of foreign issuers, including emerging markets, can include fluctuations in foreign currencies, political and economic instability, and foreign taxation issues.

Growth stocks tend to be more sensitive to changes in their earnings and can be more volatile.

Stocks of small and mid-sized companies tend to be more vulnerable to adverse developments, may be more volatile, and may be illiquid or restricted as to

resale.

The portfolio is subject to certain other risks. Please see the current Program Description for more information regarding the risks associated with an investment in the portfolio.

NOT FDIC INSURED | MAY LOSE VALUE | NO BANK GUARANTEE

Before you invest, consider whether your or the beneficiary's home state offers any state tax or other state benefits such as financial aid, scholarship funds, and protection from creditors that are only available for investments in that state's qualified tuition program.

For more information about CollegeBound 529, contact your financial advisor, call 877-615-4116, or visit www.collegebound529.com to obtain a Program Description, which includes investment objectives, risks, charges, expenses, and other important information; read and consider it carefully before investing. Invesco Distributors, Inc. is the distributor of CollegeBound 529.

Note: Not all products available at all firms. Advisors, please contact your home office.

All data provided by Invesco unless otherwise noted.